Evaxion A/S (EVAX) Form 6-K — Oct 23, 2026
Evaxion announced three-year phase 2 data for its personalized cancer vaccine EVX-01 in advanced melanoma, showing an immune response in all patients and 89% of vaccine neoantigens generating potent T-cell responses. All patients maintained the clinical response observed at two-year follow-up, with no tumor progression through the third year of EVX-01 monotherapy. This builds on two-year data showing a 75% objective response rate and 25% complete response rate. The data will be presented at ESMO 2026 in Madrid on October 24, followed by a KOL webinar on October 29.
Key figures
- Guidance
- Cash runway extending well into the second half of 2027.
- Trial size
- 16 patients
- Complete response rate
- 25%
- Extension phase responders
- 6 of 12
- Neoantigen target precision
- 89%
- Two year neoantigen hit rate
- 86%
- Patients with tumor reduction
- 15 of 16
- Patients with deepened response
- 54%
- Patients responding at two years
- 92%
- Two year objective response rate
- 75%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.